Drug Profile
Research programme: lamellarins - PharmaMar
Alternative Names: Lamellarin DLatest Information Update: 14 Apr 2009
Price :
$50
*
At a glance
- Originator PharmaMar
- Class Alkaloids
- Mechanism of Action DNA topoisomerase I inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Apr 2009 Discontinued - Preclinical for Cancer in Spain (unspecified route)
- 05 Dec 2007 This programme is still in active development
- 05 Aug 2005 This programme is still in active development - (BIO-2005)